(Alliance News) - Arecor Therapeutics PLC on Monday said its revenue increased in 2024 and said it is excited by the prospects of its "superior insulin candidate". The Cambridgeshire, England-based ...

"We are extremely pleased that the FDA granted Fast Track Designation to CUSP06," said Eric Slosberg, PhD, Chief Development Officer of OnCusp Therapeutics. "The early results from our Phase 1 trial ...

After achieving triple-digit growth with its line of pumping and feeding accessories, Willow Innovations, Inc. (Willow) is cementing its position as a comprehensive, one-stop destination for ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

All three were hooked up to machines that provided a readout of their vital signs, and all three were prepared to have a ...

DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...

In recent years, Boron Neutron Capture Therapy (BNCT) has emerged as a cutting-edge cancer treatment technology, experiencing rapid development globally. Neuboron Medical Group (Neuboron), a leading ...

The lab-grown living tissue integrated with their hearts and, within a few months, helped them pump blood more efficiently ..

Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...

Our BD 2025 strategy has transformed the company into a faster-growing, more profitable organization positioned at the forefront of long-term growth ...

Heart failure, a condition in which the heart is unable to effectively pump blood to meet the body ... with a top-tier investor syndicate as we advance this mission together for patients ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.